Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  BioPharma  /  Mooi instap moment Dendreon

BioPharma« Terug naar discussie overzicht

Mooi instap moment Dendreon

Volgen
1.743 Posts
Pagina: «« 1 ... 69 70 71 72 73 ... 88 »» | Laatste | Omlaag ↓
  4. [verwijderd] 4 juni 2007 13:58
    quote:

    geldmaker72 schreef:

    us.rd.yahoo.com/finance/external/tsmf... Wat zijn het toch een criminelen he,eerst vorige week goed nieuws brengen,koers omhoog.Nu de koers wat hoger staat dit naar buiten brengen.Gelukkig heb ik ze niet.
    Voor iemand die ze niet heeft, ben je er wel druk mee bezig. Ik heb ze trouwens wel.
  7. [verwijderd] 4 juni 2007 15:41
    Ahead of the Bell: Provenge Protestadvertisement
    Stocks mentioned in this articleDendreon Corporation (DNDN) Stock Quote, Chart, NewsRelated topics
    All Associated Press NewsNEW YORK (AP) - An advocacy group urging the Food and Drug Administration to approve Dendreon Corp.'s prostate cancer drug Provenge said it will rally in Washington Monday.

    The group is rallying against the FDA's decision to postpone the approval process of the drug as it awaits more information on its chemistry, manufacturing process and effectiveness.

    Last month, the FDA requested more clinical data on the drug candidate, sending Dendreon shares into freefall. The Seattle biotech's shares lost 64.3 percent of their value on May 9 after the agency requested the details.

    The fall came about six weeks after the stock more than doubled in one day. Shares shot up March 30, after an FDA advisory committee agreed 17 to 0 that the data submitted by Dendreon showed Provenge was safe, and voted 13 to 4 the drug was effective.

    Provenge is designed to help a man's immune system recognize the antigen in prostate cancer cells and then attack and destroy those cells. The drug is an immunotherapy, which boosts and assists the immune system, as opposed to chemotherapy, which has detrimental side effects.

    Studies showed the drug increased the life of a patient with prostate cancer by an average of 4.5 months. The study also showed there was a 41 percent overall reduction in the risk of death and 34 percent of patients were alive 36 months after treatment.

    ProvengeNow, on its Web site, said the drug is the first of its kind for prostate cancer and can effectively fight the cancer without the quality-of-life side effects of other treatments like chemotherapy.

    © 2007 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

    Back to News Home

  13. [verwijderd] 4 juni 2007 17:17
    quote:

    rac69 schreef:

    er wordt goed gekocht.
    zal toch niet door dat fake persbericht komen wat op yahoo rond dwaalt.die shotgun krijgt daar denk ik wel een probleem mee.
    ?

    DENDREON CORPORATION ANNOUNCES PROPOSED $75 MILLION CONVERTIBLE SENIOR SUBORDINATED NOTES OFFERING

    SEATTLE, June 4, 2007 - Dendreon Corporation (Nasdaq: DNDN) today announced the Company intends to offer, subject to market conditions and other factors, $75 million aggregate principal amount of convertible senior subordinated notes due 2014. This offering will be made through a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.

    The interest rate, terms of conversion, offering price, registration rights and other terms of the notes will be determined by negotiations between the Company and the initial purchaser of the notes. The Company expects to grant the initial purchaser of the notes a 30-day overallotment option to purchase up to an additional $25 million aggregate principal amount of the notes.

    The Company intends to use the net proceeds of this offering to finance its activities relating to the potential commercialization of Provenge(R) (sipuleucel-T), expand its manufacturing facilities for the commercial production of PROVENGE, fund ongoing and new clinical trials for PROVENGE and its other product candidates, support research and preclinical development activities for its other potential product candidates, and for general corporate purposes, including working capital.

    The notes and common stock issuable upon conversion of the notes have not been registered under the Securities Act of 1933 or applicable state securities laws, and unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933 and applicable state securities laws.

    This press release is neither an offer to sell nor a solicitation of an offer to buy any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

    Safe Harbor Statement

    Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, market demand for the Company's securities, pricing and other terms related to the sale of the notes, the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that
    the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

    Contact:
    Monique Greer
    Sr. Director, Corporate Communications
    Dendreon Corporation
    (206) 829-1500

  16. [verwijderd] 6 juni 2007 18:52



    Associated Press
    Dendreon Prices Offering
    Associated Press 06.06.07, 11:01 AM ET

    Related Quotes
    DNDN 8.55 - 0.20








    Biotechnology company Dendreon Corp. said Wednesday it priced its offering of $75 million aggregate principal amount of convertible senior subordinated notes due 2014.

    The offering will be made through a private placement to qualified institutional buyers and the notes will bear interest at a rate of 4.75 percent per year, Dendreon (nasdaq: DNDN - news - people ) said.

    Dendreon also has granted the initial purchaser of the notes a 30-day overallotment option to buy up to an additional $25 million of the notes.

    The sale is expected to close on Monday.

    The notes are convertible into shares of Dendreon common stock at an initial conversion rate of 97.2644 shares per $1,000 principal amount of notes, equivalent to an initial conversion price of about $10.28, subject to adjustment, the company said.

    The initial conversion price represents a premium of about 17.5 percent relative to the company's Tuesday closing stock price of $8.75.

    The company said it plans to use the proceeds to finance the future manufacturing and marketing of its prostate cancer vaccine candidate Provenge, and to support research and preclinical development for other product candidates.

    Dendreon shares fell 16 cents to $8.59 in morning trading.

    Copyright 2007 Associated Press. All rights reserved. This material may not be published broadcast, rewritten, or redistributed

    Groet.

  19. [verwijderd] 7 juni 2007 12:09
    quote:

    connect schreef:

    goede leningcondities lijkt me zo, die convertible.
    daar spreekt vertrouwen uit.

    a t lage rentepercentage
    b de relatief hoge conversiekoers.

    wie weet t "laatste nieuws" omtrent de shortpositie in dendreon.
    Daar ben ik ook altijd naar op zoek!,toerijkende info loopt altijd achter is het rottige.
1.743 Posts
Pagina: «« 1 ... 69 70 71 72 73 ... 88 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
NX FILTRATION 4,770 +0,27 +6,00%
ForFarmers 3,270 +0,13 +4,14%
THEON INTERNAT 10,420 +0,36 +3,58%
Air France-KLM 8,380 +0,24 +2,95%
CM.COM 6,940 +0,17 +2,51%
ADYEN NV 1.379,200 +24,20 +1,79%
INPOST 17,420 +0,26 +1,52%
UMG 23,730 +0,31 +1,32%
Sligro 12,600 +0,16 +1,29%
ASMI 583,200 +6,40 +1,11%
Flow Traders 21,040 +0,20 +0,96%
RELX 42,240 +0,40 +0,96%
Van Lanschot Kempen NV 43,250 +0,40 +0,93%
Accsys 0,608 +0,01 +0,83%
ASML 752,100 +4,50 +0,60%
Wolters Kluwer 152,250 +0,90 +0,59%
Pharming 0,765 +0,00 +0,59%
JDE PEET'S 18,260 +0,10 +0,55%
Sif Holding 15,040 +0,08 +0,53%
KPN 3,666 +0,02 +0,52%
UNILEVER PLC 57,080 +0,20 +0,35%
DSM FIRMENICH AG 116,750 +0,35 +0,30%
NN Group 44,050 +0,13 +0,30%
ALLFUNDS GROUP 5,185 +0,01 +0,29%
CTP 16,580 +0,04 +0,24%
Ahold Delhaize 30,950 +0,07 +0,23%
Avantium 2,235 0,00 0,00%
AZERION 1,420 0,00 0,00%
BESI 110,950 0,00 0,00%
TomTom 5,085 0,00 0,00%
Vopak 42,580 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Aperam 26,800 -1,32 -4,69%
ArcelorMittal 22,410 -0,81 -3,49%
AALBERTS NV 34,120 -1,18 -3,34%
PROSUS 40,115 -1,17 -2,83%
Alfen N.V. 12,980 -0,36 -2,66%
SBM Offshore 16,870 -0,44 -2,54%
Heineken 76,940 -1,76 -2,24%
Galapagos 27,120 -0,62 -2,24%
FASTNED 20,400 -0,45 -2,16%
SHELL PLC 31,035 -0,68 -2,13%
AMG Critical Materials N.V. 16,460 -0,35 -2,08%
SIGNIFY NV 22,040 -0,44 -1,96%
RENEWI 7,600 -0,13 -1,68%
JUST EAT TAKEAWAY 13,465 -0,22 -1,61%
Corbion 24,280 -0,38 -1,54%
RANDSTAD NV 44,090 -0,67 -1,50%
OCI 25,880 -0,35 -1,33%
PostNL 1,215 -0,02 -1,30%
Kendrion 11,140 -0,14 -1,24%
Basic-Fit 24,820 -0,28 -1,12%
Fugro 20,980 -0,20 -0,94%
HEIJMANS KON 26,350 -0,25 -0,94%
Brunel 8,800 -0,08 -0,90%
EBUSCO HOLDING 0,695 -0,01 -0,86%
ACOMO 17,520 -0,14 -0,79%
AMX 891,73 -7,06 -0,79%
Aegon 5,662 -0,04 -0,70%
Nedap N.V. 57,400 -0,40 -0,69%
WDP 23,220 -0,16 -0,68%
Wereldhave 14,660 -0,10 -0,68%
ING 16,050 -0,11 -0,66%
Akzo Nobel 62,920 -0,40 -0,63%
Eurocommercial Properties 24,200 -0,15 -0,62%
Arcadis 63,250 -0,35 -0,55%
TKH 37,500 -0,20 -0,53%
BAM 4,386 -0,02 -0,50%
NSI 20,100 -0,10 -0,50%
Philips Koninklijke 29,060 -0,14 -0,48%
Fagron 17,880 -0,08 -0,45%
EXOR NV 96,400 -0,40 -0,41%
IMCD 151,400 -0,55 -0,36%
AEX 910,19 -2,58 -0,28%
ASCX 1.250,26 -3,35 -0,27%
ASR Nederland 43,370 -0,11 -0,25%
B&S Group SA 4,700 -0,01 -0,21%
Vastned 24,100 -0,05 -0,21%
ABN AMRO BANK N.V. 15,650 -0,01 -0,06%
vlag naam koers verschil relatief verschil
AEX 910,19 -2,58 -0,28%
AEX GR 3.557,43 -10,09 -0,28%
Germany40^ 19.101,40 +34,93 +0,18%
FTSE 100 8.190,61 -113,01 -1,36%
EURO50 4.957,14 0,00 0,00%
US30^ 42.070,60 0,00 0,00%
Nasd100^ 20.096,10 0,00 0,00%
US500^ 5.750,25 0,00 0,00%
Japan225^ 39.361,30 0,00 0,00%
VD-NEW 18,24 -0,14 -0,77%
#/^ Index indications calculated real time, zie disclaimer